Reference table
Has the FDA finalized anything on the peptides recommended in July 2026?
The answer
No. As of 2026-09-02, not one of the six peptides the advisory committee recommended has an FDA final action on record, and the most recent section 503A bulks-list rule was published on February 19, 2019 — before every event this index tracks.
A recommendation from an advisory committee is not permission, and the interval between the two is where almost every misreading of this subject lives. The committee met on July 23 and 24, 2026; a pharmacy may compound with a substance only once the FDA completes rulemaking that places it on the section 503A list. This page tracks whether that has happened.
It is written to be checked rather than believed. Below the table is a log of every check run against the Federal Register and the FDA's own list document, with the date, the search, what came back, and the controls that prove the search was working. An absence probe with no control is the perfect instrument for reporting a false negative, and this page publishes nothing but absences.
Denominator
The rows are the peptides this index records as carrying a July 2026 advisory-committee vote, and nothing more; the committee reviewed seven substances and this index tracks each of them. The vote tallies are REPORTED figures: the FDA has published no minutes, transcript or vote summary for the meeting, and the tallies this index carries are attributed on each monograph to the two independent law-firm accounts it read them from. The final-action column is not a summary of FDA activity generally; it records whether this index has found a final action for that specific substance on the dates logged below.
Rows are read from MOLECULES[].record[] (the July 2026 entries), MOLECULES[].finalized (absent on every row), FINAL_ACTION_CHECKS[] — the registry's July 2026 ledger entries for the recommendation column, and MOLECULES[].finalized for the final-action column — a slot that is absent on every molecule in this index and renders as an explicit "none recorded" rather than a blank. A single registry edit fills it, on the day an action lands.
| Molecule | July 2026 outcome | Status today | FDA final action |
|---|---|---|---|
| BPC-157 | Recommended for listing | PCAC-recommended · pending | none recorded as of 2026-09-02 |
| KPV | Recommended for listing | PCAC-recommended · pending | none recorded as of 2026-09-02 |
| Semax | Recommended for listing | PCAC-recommended · pending | none recorded as of 2026-09-02 |
| TB-500 | Recommended for listing | PCAC-recommended · pending | none recorded as of 2026-09-02 |
| Epitalon | Recommended for listing | PCAC-recommended · pending | none recorded as of 2026-09-02 |
| MOTS-c | Recommended for listing | PCAC-recommended · pending | none recorded as of 2026-09-02 |
| DSIP | Not recommended | No lawful route | none recorded as of 2026-09-02 |
**The check log, newest first.** Each entry records a check this index actually ran, what it searched, what came back, and the controls that were run beside it.
**2026-09-02** — The Federal Register API, for any document type from the Food and Drug Administration matching "bulk drug substances" and compounding published on or after January 1, 2026; and separately for every FDA document of type RULE matching "503A" and "bulk drug substances", newest first. No final rule. The 2026 search returned five documents and every one is a Notice: the August 31 information-collection request on registration of human drug compounding outsourcing facilities, the August 28 notice on compounding animal drugs, the June 26 and May 1 notices on the section 503B clinical-need list, and the April 16 notice of the Pharmacy Compounding Advisory Committee meeting. The rule search returned six documents, the most recent bulks-list rule being "List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act", 84 FR 4696, published February 19, 2019 — which predates every event this index tracks. Controls in the same run: a term the register certainly holds returned the maximum result count with documents dated the day of the check, and an invented term returned zero.
**2026-09-02** — The FDA section 503A bulks list document itself, read in full, for any peptide moved into Category 1 following the July 2026 advisory committee recommendations. No movement. The document is still the one updated May 14, 2026, and none of the six recommended peptides appears in any of its three categories. Fetched with curl and a browser user agent; in the same run a known-good FDA page returned 200 and an invented FDA path returned 404.
Nothing on this page anticipates an outcome. The FDA may act on some of these substances, on all of them, or on none, and this index publishes the record rather than a forecast; the pending page carries what a recommendation does and does not confer, and the 2026 record carries the chronology the recommendations sit inside.
Other tables
Evidence reviews